Skip to main content
. 2017 Sep 8;7:10995. doi: 10.1038/s41598-017-11316-8

Figure 1.

Figure 1

Therapeutic efficacy of CN2097 in reducing post-traumatic neuroinflammation in the injured cerebral cortex. Western blot analysis was performed on cortical samples following CCI. Rats were injected i.p. with CN2097 (10 mg/kg) or vehicle (0.9% NaCl) at 1 and 2 h post-TBI (n = 4 rats/group). Cortical samples were collected at 4 h (A) or 24 h (B) after TBI. (A) CN2097 significantly lowered the post-traumatic production of TNF-α and IL-1β at 4 h post-TBI. The fully processed, biologically active forms of these proinflammatory cytokines are shown. C: contralateral, uninjured cortex. (B) CN2097 inhibited the post-traumatic influx of monocytes to the injured cortex, as assessed by the level of expression of CD68, and reduced the synthesis of MMP9 (pro-MMP9 is shown) at 24 h post-TBI. The expression of CD68 and pro-MMP9 was undetectable in the contralateral cortex. Data represent mean ± SEM. The images shown are cropped. The full-length original images are shown in Fig. S1.